Healthcare
Fulcrum Therapeutics, Inc.(FULC)
Live Price
Offline$3.70
+5.71% today
1Y Change
-46.23%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $380.00M
- Revenue Growth
- -100.0%
- EPS Growth
- -637.5%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Fulcrum Therapeutics, Inc. (FULC) is a Healthcare stock with a market cap of $380.00M and listed on NASDAQ. The stock last traded around $3.70 and down 46.2% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of -637.5%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS -637.5%, free cash flow -2319.0% with operating margin 0.0% and ROIC -25.5%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines FULC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-100.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -100.0% and EPS is at -637.5%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -7.0% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | โ | +1.9% | +3.3% | -46.4% |
2026 Feb 24, 2026 | +0.0% | +4.7% | -8.3% | -21.9% |
2025 Oct 29, 2025 | -6.9% | -8.1% | -15.9% | +20.9% |
Benchmark Edge
FULC vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
FULC
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
FULC Max Drawdown
-78.49%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for FULC and SPY.
Company Overview
Fulcrum Therapeutics, Inc.
NASDAQ Global Market
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
- Leadership
- Alexander C. Sapir
- IPO Date
- Jul 18, 2019
- Employees
- 45
- Street Address
- 26 Landsdowne Street
- Mailing
- Cambridge, MA, 02139
- Region
- Cambridge, MA, US
- Reporting Currency
- USD
- Investor Line
- 617 651 8851
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 1.6
Growth
- Revenue
- -100.0%
- EPS
- -637.5%
- Free Cash Flow
- -2319.0%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -27.8%
- ROIC
- -25.5%
Balance Sheet
- Debt/Equity
- 0.02
- Current Ratio
- 34.33
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.